reports
Revolution Medicines Announces First Patient Randomized in the RASolut...
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the RASolute 304 trial. RASolute 304 is a global, open-label, Phase 3 clinical trial evaluating the safety and efficacy of daraxonrasib, a RAS(ON) multi-selective in...
Sensient Technologies Corp: 1 director
A director at Sensient Technologies Corp sold 4,518 shares at 94.809USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Wedbush Research
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
FTNT FORTINET INC.
CNK CINEMARK HOLDINGS INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMD ADVANCED MICRO DEVICES INC.
ARVN ARVINAS HOLDING
LYFT LYFT
GOSS GOSSAMER BIO
DT DYNATRACE INC.
RVMD REVOLUTION MEDICINES
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
DASH DOORDASH
FHTX FOGHORN THERAPEUTICS
STX SEAGATE TECHNOLOGY HLDGS PLC
ALIT FOLEY TRASIMENE ACQUISITION CORP
APP APPLOVIN CORP
CCSI CONSENSUS CLOUD SOLUTIONS INC
CMPX COMPASS THERAPEUTICS
MLTX MOONLAKE IMMUNOTHERAPEUTICS
TYRA TYRA BIOSCIENCES INC
DNTH DIANTHUS THERAPEUTICS INC
DBD DIEBOLD NIXDORF INCORPORATED
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Revolution Medicines Reports Third Quarter 2025 Financial Results and ...
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line metastatic PDAC this yearDaraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug De...
Macerich Reports Third Quarter 2025 Earnings Results
Macerich Reports Third Quarter 2025 Earnings Results SANTA MONICA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) has released its Third Quarter 2025 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at . As previously announced, management will hold a conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) today, Tuesday, November 4, 2025, to discuss quarterly results. Participants who wish to join the conference by telephone must register using the dial-in registration link below to receiv...
Revolution Medicines to Participate in November 2025 Investor Conferen...
Revolution Medicines to Participate in November 2025 Investor Conferences REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in two upcoming investor conferences. Details of the company’s participation are as follows: Guggenheim 2nd Annual Healthcare Innovation Conference Fireside Chat: Tuesday, November 11 at 9:...
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Thomas Yip
- Yun Zhong
KURA KURA ONCOLOGY INC.
CTMX CYTOMX THERAPEUTICS INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
NTLA INTELLIA THERAPEUTICS INC.
ARVN ARVINAS HOLDING
RVMD REVOLUTION MEDICINES
OCUP OCUPHIRE PHARMA INC
TVTX TRAVERE THERAPEUTICS INC
NUVB NUVATION BIO INC (A)
DAWN DAY ONE BIOPHARMACEUTICALS INC
TNGX TANGO THERAPEUTICS
HOWL INC
GMTX WEREWOLF THERAPEUTICS INC
SGMT GEMINI THERAPEUTICS INC
RNAC SAGIMET BIOSCIENCES INC
MAZE CARTESIAN THERAPEUTICS INC
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
Macerich Declares the Quarterly Dividend on Its Common Shares
Macerich Declares the Quarterly Dividend on Its Common Shares SANTA MONICA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of the Macerich Company (NYSE: MAC) declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on December 29, 2025, to stockholders of record at the close of business on December 15, 2025. About Macerich Macerich is a fully integrated, self-managed, self-administered real estate investment trust (REIT). As a leading owner, operator, and developer of high-quality retail real estate in densely populated and attrac...
Revolution Medicines to Report Financial Results for Third Quarter 202...
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025 REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines’ senior management team will host a webcast to discuss the financia...
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib G...
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to daraxonrasib, the company’s RAS(ON) multi-selective inhibitor, for the treatment of pancreatic cancer. “We are gratified the FDA has granted Orphan Dru...
- Wedbush Research
FATE FATE THERAPEUTICS INC
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
2303 UNITED MICROELECTRONICS CORP.
ROKU ROKU INC. CLASS A
TSEM TOWER SEMICONDUCTOR LTD
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
RZLT REZOLUTE
IMNM IMMUNOME
TNGX TANGO THERAPEUTICS
GFS INC
TYRA GLOBALFOUNDRIES INC
NUVL TYRA BIOSCIENCES INC
BCAX NUVALENT INC
BBOT BICARA THERAPEUTICS INC.
BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
- Wedbush Research
TSLA TESLA INC
TPH TRI POINTE HOMES INC.
PEGA PEGASYSTEMS INC.
MELI MERCADOLIBRE INC.
TMHC TAYLOR MORRISON HOME CORPORATION
MHO M/I HOMES INC.
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
NUVL NUVALENT INC
BCAX BICARA THERAPEUTICS INC.
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
Revolution Medicines to Present Updated Elironrasib Safety and Efficac...
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer (NSCLC) who had received a prior KRAS(OF...
- Wedbush Research
NVCR NOVOCURE LTD.
OSTK OVERSTOCK.COM INC.
ISR ISORAY
AAPL APPLE INC.
RCUS ARCUS BIOSCIENCES
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TCRX TSCAN THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
NUVL NUVALENT INC
BCAX BICARA THERAPEUTICS INC.
TLX TELIX PHARMACEUTICALS LIMITED
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
ISR ISORAY
RCUS ARCUS BIOSCIENCES
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
TCRX TSCAN THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
NUVL NUVALENT INC
BCAX BICARA THERAPEUTICS INC.
TLX TELIX PHARMACEUTICALS LIMITED
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Yun Zhong
NVCR NOVOCURE LTD.
MNKD MANNKIND CORP.
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
ARDX ARDELYX INC
WVE WAVE LIFE SCIENCES
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
ISR ISORAY
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
RZLT REZOLUTE
NUVB NUVATION BIO INC (A)
NUVL NUVALENT INC
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
UEC URANIUM ENERGY CORP
NEO NEOGENOMICS INC.
MO ALTRIA GROUP INC
HNRG HALLADOR ENERGY CO.
CODI COMPASS DIVERSIFIED HOLDINGS
CBOE CBOE GLOBAL MARKETS INC
ABC AMERISOURCEBERGEN CORPORATION
KO COCA-COLA COMPANY
PTGX PROTAGONIST THERAPEUTICS
UAMY UNITED STATES ANTIMONY CORP.
COKE COCA-COLA CONSOLIDATED INC.
RVMD REVOLUTION MEDICINES
PCVX VAXCYTE
NVTS NAVITAS SEMICONDUCTOR CORP
GLUE MONTE ROSA THERAPEUTICS INC
AIRS AIRSCULPT TECHNOLOGIES INC
JANX JANUX THERAPEUTICS INC
NAMS NEWAMSTERDAM PHARMA COMPANY B.V.
ATLX ATLAS LITHIUM CORPORATION
ZYME ZYMEWORKS INC.
NB NIOCORP DEVELOPMENTS LTD.
METC RAMACO RESOURCES INC.
BNTC BENITEC BIOPHARMA INC
CDTX CIDARA THERAPEUTICS INC.
ABAT AMERICAN BATTERY TECHNOLOGY COMPANY
ONEG ONECONSTRUCTION GROUP LIMITED
SION SIONNA THERAPEUTICS INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.